Investor
Novo Holdings
Named as a participating investor in 5 funding announcements in 2026. Every round below links to the announcement that named them.
For investors, banks and advisers
Want this delivered, filtered to your mandate?
Every morning: the rounds in your sectors, stages and regions. The investor index as an export. First access to what verified founders say their companies need next, on the founder's terms. Tell us what you are looking for and a person replies with what is available for your desk.
Where it invests
Sectors named in these rounds
Invests alongside
Named on the same announcements
Counted from the announcements only. Appearing on the same round is a fact about the round, not a statement about a relationship.
Rounds joined
Where Novo Holdings participated
| Company | Raised | Round | Announced | Led by | Source |
|---|---|---|---|---|---|
| Expedition Therapeutics USA | $115M | Series B | 2026-08-05 | led by General Atlantic | announcement |
| Claris Biotherapeutics USA | $118M | Series B | 2026-08-03 | led by Samsara Biocapital, Catalio Capital Management | announcement |
| Crystalys Therapeutics USA | $130M | Series B | 2026-07-22 | led by Frazier Life Sciences | announcement |
| Windward Bio Switzerland | $165M | Undisclosed | 2026-05-05 | led by OrbiMed | announcement |
| Adcendo Denmark | $75M | Series C | 2026-04-14 | led by Jeito Capital | announcement |
Investor names are read from the funding announcements and grouped by spelling. A round names its investors the way the publisher did; a firm not named in an announcement does not appear here. Corrections: info@afterraise.com.